Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
68.50    -2.00 (-2.84%)
Bid:
68.00
Ask:
69.00
Spread: 1.00 (1.471%)
Market Cap: £320.96m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Final Results

24 Aug 2005 07:00

Readybuy PLC24 August 2005 READYBUY PLCPRELIMINARY RESULTSYear ended 30 April 2005 CHAIRMAN'S STATEMENT Results Our results for the year ended 30 April 2005 show turnover of £313,000 (2004:£19,000) and operating losses of £252,000 (2004: £343,000). Furthermore, as theboard has decided to withdraw from food manufacturing, additional provisions of£804,000 have been made at the year-end. These relate to the write-off ofgoodwill and the write-down of machinery values. Although some progress was made during the year and several listings wereachieved, the level of business was not sufficient to maintain a viablemanufacturing unit. Since the year-end, the manufacturing unit has been closed and the machinery hasbeen sold. Paul Bennett, the Chief Executive, left the company on 22 July and we wish tothank him for his efforts in trying to build the business. The board is now considering the options available to the Group and will updateshareholders in due course. I would like to thank all the employees for their hard work during the difficulttrading period Colin DaviesChairman24 August 2005 READYBUY PLC CONSOLIDATED PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 30 APRIL 2005 Audited Audited 01/05/04 to 30/04/05 01/05/03 to 30/04/04 £000's £000'sTurnover 313 19 Operating Loss (252) (343) Provision for loss on operations to be discontinued (804) - (1056) (343)Interest Payable (4) (6)Interest Receivable 2 6 Loss before Taxation (1058) (343) Taxation (45) 45 Loss after taxation (1103) (298)Dividends - -Deficit for the year (1103) (298) Loss Per Share (note 3) (6.1p) (2.2p) The Group's trading activities were terminated in July 2005, therefore all ofthe above activities are classified as discontinued. READYBUY PLC CONSOLIDATED BALANCE SHEET AT 30 APRIL 2005 Audited Audited 30 April 2005 30 April 2004 £000's £000'sFixed AssetsIntangible Assets - 646Tangible Assets - 218 - 864Current AssetsStocks 2 7Debtors 44 82Cash at Bank and in Hand 169 429 215 518 Creditors: amounts due within one year (194) (323) Net current assets 21 195Total assets less current liabilities 21 1059Creditors: amounts falling due after more than one year - (25) Net Assets 21 1034 Share Capital and ReservesCalled up Share Capital 93 90Share Premium Account 1329 1242Profit and Loss Account (1401) (298) Equity and Non-Equity Shareholders' funds 21 1034 READYBUY PLC CONSOLIDATED CASHFLOW STATEMENT FOR THE YEAR ENDED 30 APRIL 2005 Audited Audited 01/05/04 to 30/04/05 01/05/03 to 30/04/04 £000's £000's Net Cash outflow from operating activities (80) (407) Returns on investments and servicing of financeInterest Paid (4) (6)Interest Received 2 6Net Cash Inflow/(Outflow) from servicing of (2) -Finance Capital Expenditure Payments to acquire tangible assets (9) (77)Sale of tangible assets 1 35 Net Cash outflow from Capital Expenditure (8) (42) Purchase of Subsidiary undertaking - (272)Net overdraft acquired with subsidiary undertaking - (6)Net Outflow from acquisitions - (278) Net Cash outflow before use of (90) (727)liquid resources and financing Financing Issue of equity Share Capital 90 1169Capital element of lease payments (34) (19)Repayment of term loans - (220)Net Inflow from financing 56 930 (Decrease)/Increase in Cash (34) 203 READYBUY PLCFOR THE YEAR ENDED 30 APRIL 2005 Notes 1. The preliminary financial results for the year ended 30 April 2005 were approved by the Directors on 24 August 2005. 2. There were no recognised gains or losses other than the result for the period. 3. The calculation of earnings per share is based upon the loss after taxation of £1,103,000 (2004: £298,000) divided by the weighted average number of ordinary shares in issue during the year which was 18,066,870 (2004: 13,585,434). 4. The preliminary statement is available from the Company's registered office at: Television House, 10-12 Mount Street, Manchester, M2 5NT. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
30th Jul 20257:00 amRNSAvacta to Present at ESMO Congress
28th Jul 20257:48 amRNSAgreement to Sell Coris Bioconcept SRL
21st Jul 20257:00 amRNSPayment of Convertible Bond Installment
17th Jul 20257:00 amRNSEquity fundraise of £3.25 million
2nd Jul 20255:00 pmRNSResult of AGM
2nd Jul 20257:00 amRNSQ2 2025 Business Update
1st Jul 20257:00 amRNSManagement Team Appointments
30th Jun 20253:00 pmRNSAppointment of Zeus Capital as Joint Broker
19th Jun 20257:00 amRNSNew Response in Phase 1b Trial
9th Jun 20255:15 pmRNSPosting of Annual Report and Revised Notice of AGM
6th Jun 20257:00 amRNSPreliminary Full Year 2024 Results
4th Jun 20257:00 amRNSAvacta Change in Prelim Date Part 2
28th May 20257:00 amRNSBoard appointments
27th May 20257:00 amRNSUpdate on timing of preliminary results
15th May 20257:00 amRNSNotice of Results
12th May 202512:00 pmRNS-RInvestor Webinar
8th May 20257:30 amRNSBlock Listing Application to AIM
29th Apr 20257:00 amRNSBoard change
28th Apr 20255:52 pmRNSBlock Listing Six Monthly Return
28th Apr 20257:01 amRNSAvacta presents preclinical data at AACR
28th Apr 20257:00 amRNSAvacta presents data from lead candidate at AACR
23rd Apr 20257:00 amRNSIssue of Equity and Total Voting Rights
31st Mar 20257:00 amRNSAvacta Quarterly Update
26th Mar 20257:00 amRNSAvacta Announces Presentations at AACR
25th Mar 20257:00 amRNSAvacta Completes Launch Diagnostics Sale
10th Mar 20257:00 amRNSAvacta to Present at Leerink Healthcare Conference
7th Mar 20258:40 amRNSAvacta announces data update for AVA6000
7th Mar 20257:42 amRNSAvacta to sell Launch Diagnostics
4th Feb 20257:00 amRNSAppointment of Joint Broker
21st Jan 20253:09 pmRNSIssue of Equity and Total Voting Rights
16th Jan 20257:00 amRNSAvacta Announces Data from AVA6000 Phase 1 trial
13th Jan 20257:00 amRNSAvacta Appoints Chief Financial Officer
12th Dec 20247:00 amRNSCompletion of Dose Escalation and RDE Arms
30th Oct 20247:00 amRNSR&D Spotlight focusing on pipeline advances
28th Oct 20247:00 amRNSBlock Listing Six Monthly Return
24th Oct 20247:00 amRNSAvacta Reports Pipeline Avances at EORTC
21st Oct 20244:00 pmRNSIssue of Equity and Total Voting Rights
21st Oct 20247:00 amRNSAvacta and Tempus Enter Strategic Collaboration
17th Oct 20247:00 amRNSAvacta Expands its Pipeline
15th Oct 20247:00 amRNSAvacta appoints Chief Scientific Officer
10th Oct 20247:00 amRNSAvacta Unveils Pipeline Expansion at EORTC 2024
30th Sep 20247:00 amRNSInterim Results
16th Sep 20247:00 amRNSAvacta Reported Updated Phase 1 Data of AVA6000
12th Sep 20247:00 amRNSNotice of Results
9th Sep 20247:00 amRNSAvacta to present clinical data at ESMO Congress
2nd Sep 20243:53 pmRNSDirector/PDMR Shareholdings and TVR
18th Jul 20247:00 amRNSConvertible Bond Payment
26th Jun 20242:46 pmRNSResult of AGM
26th Jun 20247:00 amRNSAGM Business Update
20th Jun 20247:00 amRNSShaun Chilton appointed Non-Executive Chairman

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.